Funding for this research was provided by:
Etoile de Martin
Fédération Enfants & Santé
Received: 20 October 2017
Accepted: 29 June 2018
First Online: 6 July 2018
Ethics approval and consent to participate
: This study was approved by the ethics committee of Nancy-Brabois Hospital (CPP Est III), registered 11/08/2016. The French agency for drug safety and health products ratified this study on 10/26/2016. Three substantial modifications were approved. The French Advisory Committee on the Treatment of Research Information in the field of Health validated ARPEGE on 10/14/2015. Trial registration: ID-RCB number: 2015-A00975–44, ClinicalTrials.gov Identifier: NCT02827552, registered 7/6/2016.Prior to inclusion of the patient, a written consent is obtained from the holder(s) of parental authority and/or the child (with a document adapted to his age), after they have been fully informed by the investigator during an interview and after free time-lapse. A Childhood Cancer Parents Association validated the information materials and consent forms.
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.